Revolution Medicines SVP Cislini sells $158,599 in shares

Revolution Medicines' Senior Vice President and General Counsel, Jeff Cislini, recently sold 765 shares of the company's stock on September 25, 2026, for a combined total of $158,599. The shares were sold at a price of $207.3201 per share, which is nearly in line with the stock's present trading price of $204.48. This transaction was carried out under a pre-established Rule 10b5-1 trading plan that Cislini put in place on May 22, 2026.

The sale occurred at a time when Revolution Medicines shares have experienced a remarkable 344% increase over the past year and a 121% rise in the last six months.

Post the sale, Cislini's ownership in Revolution Medicines common stock has been reduced to 51,776 shares, which now includes 37,088 restricted stock units. According to InvestingPro evaluations, the stock currently seems to be overvalued when compared to its estimated Fair Value. For those interested in gaining further insights, Revolution Medicines is included in the 1,400+ US equities that InvestingPro provides detailed Pro Research Reports for, which are accessible exclusively through their platform.

Recently, Revolution Medicines has garnered considerable attention after the FDA granted approval to its drug, Rasonque, for treating second-line metastatic pancreatic ductal adenocarcinoma. This approval, which was based on the RASolute 302 study, revealed that daraxonbesib nearly doubled the median overall survival compared to traditional chemotherapy treatments.

With a wholesale acquisition cost of $39,800 for a 30-day supply, the drug's market potential is significant. Following this significant development, several leading financial institutions have adjusted their outlooks on Revolution Medicines.

Needham increased its price target from $240 to $275 and maintained a Buy rating, Guggenheim likewise increased its price target to $275 with a Buy rating, Brookline Capital Markets initiated coverage with a Buy rating and a price target of $318, and Goldman Sachs initiated coverage with a Buy rating and a price target of $267. Morgan Stanley provided an overweight rating with a price target of $255, pointing to the company's robust de-risked commercial foundation following the approval of Rasonque.

These developments demonstrate the strong confidence the financial community has in Revolution Medicines' future prospects. This report was created with the assistance of AI and subsequently reviewed by an editor. For additional details, please refer to the Terms and Conditions.